Premium
In vitro determination of cytotoxic drug response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA)
Author(s) -
Csóka Katalin,
Tholander Bengt,
Gerdin Eva,
de la Torre Manuel,
Larsson Rolf,
Nygren Peter
Publication year - 1997
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19970917)72:6<1008::aid-ijc15>3.0.co;2-0
Subject(s) - microculture , cytotoxicity , ovarian carcinoma , cytotoxic t cell , in vitro , in vivo , carcinoma , drug , medicine , pharmacology , cancer research , chemosensitivity assay , oncology , pathology , immunology , chemistry , ovarian cancer , biology , cancer , biochemistry , microbiology and biotechnology
The fluorometric microculture cytotoxicity assay (FMCA), a short‐term in vitro assay based on the concept of total tumor cell kill, was used for testing the cytotoxic drug sensitivity of tumor cells from patients with ovarian carcinoma. A total of 125 fresh specimens was obtained, 98 (78%) of which were analyzed successfully. Data from 45 patients were available for clinical correlations. The FMCA appeared to yield clinically relevant cytotoxic drug sensitivity data for ovarian carcinoma as indicated by a comparison with tumor samples obtained from patients with non‐Hodgkin's lymphoma or kidney carcinoma. Considering the most active single agent in vitro actually given in vivo, and using the median drug activity among all ovarian carcinoma samples as a cut‐off, the sensitivity of the assay and its specificity were 75 and 52%, respectively. Cross‐resistance in vitro was frequently observed between standard drugs but not between standard drugs and Taxol. Ten percent of the specimens showed an extreme resistance for at least 4 of 6 of the drugs investigated. Int. J. Cancer 72:1008–1012, 1997. © 1997 Wiley‐Liss, Inc.